Therapeutic applications of monoclonal antibodies

Systematic Reviews in Pharmacy

Volumn 2, Issue 1, 2011, Pages 37-42

  Prajapati, D S ^a   Shah, J S ^a   Dave, J B ^a   Patel, C N ^a  

^a Shri Sarvajanik Pharmacy College   (India)

Author keywords

Breast cancer; Leukemia; Monoclonal antibody; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GOLIMUMAB; INFLIXIMAB; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PLACEBO; RITUXIMAB; TRASTUZUMAB;

ACUTE GRAFT REJECTION; ANKYLOSING SPONDYLITIS; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; BACKACHE; BLEEDING; BLOOD PRESSURE; BODY PAIN; BRAIN CAPILLARY LEAK SYNDROME; BREAST CANCER; BRONCHITIS; BRONCHOSPASM; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEPATITIS B; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; INTESTINE PERFORATION; ISCHEMIC HEART DISEASE; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LUNG INFILTRATE; LUPUS VULGARIS; LYMPHOCYTE DEPLETION; NONHODGKIN LYMPHOMA; NONHUMAN; NOSE SEPTUM PERFORATION; OPPORTUNISTIC INFECTION; OVARY CANCER; PAIN; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY ARREST; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SWELLING; SYNCOPE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VIRUS REACTIVATION;

EID: 80051880277     PISSN: 09758453     EISSN: 09762779     Source Type: Journal    
DOI: 10.4103/0975-8453.83437     Document Type: Review

References (45)

1. Washington DC. Biotechnology industry organization Whatis biotechnology? J Pharma Res 1989;45:231.
2. Leo G, Robert G, Zak TC. Biotech resources: Monoclonal antibody technology-the basics. J Pharma Res 1998;85:65.
3. Trehan K. Biotechnology. 5. New Delhi: Sutan Chand and Company Ltd.; 1993.
4. Waldmann TA. Immunotherapy: Past, present and future. Nat Med 2003;9:269-77. (Pubitemid 36362781)
5. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7. (Pubitemid 18091075)
6. Velcheti V, Viswanathan A, Govindan R. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: A single institutional survey. J Thorac Oncol 2006;1:501. (Pubitemid 47181431)
7. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7:548-52. (Pubitemid 32448320)
8. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68. (Pubitemid 37176793)
9. Diermeier S. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005;304:604-19. (Pubitemid 40321136)
10. Anastasi S. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 2005;24:4540-8. (Pubitemid 41032617)
11. Nahta R. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28. (Pubitemid 41713383)
12. Nahta R. P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004;64:3981-6. (Pubitemid 38697313)
13. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, et al. Development of herceptin resistance in breast cancer cells. Cytometry A 2004;57:86-93. (Pubitemid 38197598)
14. Romand EH. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;20:1673-84.
15. John ML. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005;5:543-9.
16. Peter DS. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:1-10.
17. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. J Oncogene 2003;2:6570-8. (Pubitemid 37372337)
18. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
19. Burton C, Kaczmarski R, Mohamed JR. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-1. (Pubitemid 36741603)
20. Williams SC. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum 2009;60:408-18.
21. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-44. (Pubitemid 351339884)
22. Choy EH, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol 1998;37:484-90.
23. Ronald F, Van V. Treatment of rheumatoid arthritis: State of the art 2009. Nat Rev Rheumatol 2009;5:531-41.
24. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244-79.
25. Janice MR, Clark JR. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-8.
26. Smolen JS. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
27. Hjardem E. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor α inhibitor? Ann Rheum Dis 2007;66:1184-9. (Pubitemid 47309735)
28. Emery P. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomized, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
29. Bejarano V. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
30. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15. (Pubitemid 37409707)
31. Emery P. Abatacept has beneficial effects in rheumatoid arthritis patients. Clin Exp Rheumatol 2005;23:767-8.
32. Taylor PC, Feldmann M. Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-82.
33. Isaacs JD. Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther 2009;11:225.
34. Sandborn WJ, Feagan BG, Stoinov S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38. (Pubitemid 47080387)
35. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-6. (Pubitemid 40593341)
36. U.S. Food and Drug Administration (FDA). FDA approves Cimzia to treat Crohn's disease. FDA News. Rockville, MD; April 22, 2008. Available from: http://www.fda.gov/bbs/topics/NEWS/2009/NEW01821.html [last accessed on 2009 May 20].
37. UCB Group. Cimzia approved in the US for the treatment of moderate to severe Crohn's disease. Press Release-Regulated Information. UCB News. Brussels, Belgium; UCB; April 22, 2008. Available from: http://www.ucb-group.com/media- centre/3384.asp [last accessed on 2009 May 20].
38. Choy EH, Hazleman B, Smith M. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41:1133-7. (Pubitemid 35203540)
39. National Horizon Scanning Centre (NHSC). Certolizumab pegol for moderate to severe Crohn's disease-horizon scanning review. Birmingham, UK: NHSC; 2004.
40. UCB, Inc. Cimzia® (certolizumab pegol). Prescribing Information. Smyrna, GA; UCB; revised April 2008. Available from: http://www.ucb-group.com/ documents/CIMZIA- Prescribing-Information.pdf [last accessed on 2009 May 20].
41. UCB. UCB's Cimzia (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis. UCB News. Brussels, Belgium; UCB; May 14, 2009. Available from: http://www.ucb.com/news/ newsdetail?det=1314787 [last accessed on 2009 May 20].
42. Barnes T, Moots R. Targeting nanomedicines in the treatment of rheumatoid arthritis: Focus on certolizumab pegol. Int J Nanomedicine 2007;2:3-7. (Pubitemid 46901774)
43. Smolen J. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor-α inhibitors (GO-AFTER study): A multicentre, randomized, double blind, placebo controlled, phase III trial. Lancet 2009;374:210-21.
44. Leo G, Robert G, Zak TC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
45. Alex J, Shirwaikar AA. Novartis product page for Simulect (basiliximab for injection). N Engl J Med 2005;125:203.